A double-blinded randomised controlled study of the value of sequential intravenous and oral magnesium therapy in patients with chronic low back pain with a neuropathic component
Yousef AA, Al-deeb AE
Published in Anaesthesia
Methodology
Double-blind randomized placebo-controlled trial of sequential IV then oral magnesium therapy in adults with chronic neuropathic low back pain, with numeric pain scores and lumbar spine mobility measured to 6 months.
Key Findings
Two weeks of intravenous magnesium followed by four weeks of oral magnesium reduced pain intensity (NRS) and improved lumbar range of motion out to six months in patients with refractory chronic low back pain with a neuropathic component.
Conclusions
Our findings show that a 2-week intravenous magnesium infusion followed by 4 weeks of oral magnesium supplementation can reduce pain intensity and improve lumbar spine mobility during a 6-month period in patients with refractory chronic low back pain with a neuropathic component.
Limitations
Single-centre trial with modest sample (n=80), intensive intravenous protocol limiting real-world applicability, and unblinding risk from infusion-related effects.
Supplements Studied
Our findings show that a 2-week intravenous magnesium infusion followed by 4 weeks of oral magnesium supplementation can reduce pain intensity and improve lumbar spine mobility during a 6-month period in patients with refractory chronic low back pain with a neuropathic component.
Outcomes Measured
Two weeks of intravenous magnesium followed by four weeks of oral magnesium reduced pain intensity (NRS) and improved lumbar range of motion out to six months in patients with refractory chronic low back pain with a neuropathic component.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.